Literature DB >> 16202775

Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe.

Jeannette E Dankert-Roelse1, Marieke E Mérelle.   

Abstract

We reviewed the published results of European prospective cohort and controlled studies and 1 randomized controlled study to assess whether newborn screening (NBS) for cystic fibrosis (CF) leads to an improved prognosis. We used long-term survival, early mortality, nutritional and pulmonary status, and the number of hospital admissions as outcome measures. Effects on reproductive behavior of the parents and relatives were also assessed. In 2 studies, a similar trend for improved long-term survival rate of the screened cohort was observed, whereas in 2 other studies CF NBS appeared to prevent CF-related deaths in infancy and early childhood. Screened patients born in the last 2 decades showed normal growth for height and weight from infancy until late childhood. In most studies, patients who were screened were found to have less lung damage than their non-screened peers. CF NBS significantly reduced the number of affected children who ever required hospitalization. In Brittany, France, a reduction of 15.7% in CF prevalence at birth was attributed to the introduction of a NBS program for CF. We conclude that there is accumulating evidence that CF NBS prevents early CF-related deaths and leads to a substantial and prolonged health gain for patients with CF.

Entities:  

Mesh:

Year:  2005        PMID: 16202775     DOI: 10.1016/j.jpeds.2005.08.009

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening.

Authors:  Lacrecia J Britton; Gabriela R Oates; Robert A Oster; Staci T Self; Robert B Troxler; Wynton C Hoover; Hector H Gutierrez; William T Harris
Journal:  Pediatr Pulmonol       Date:  2016-08-24

Review 2.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

Review 3.  Newborn screening for cystic fibrosis.

Authors:  Jack K Sharp; Michael J Rock
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

4.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

5.  Risk factors for the progression of cystic fibrosis lung disease throughout childhood.

Authors:  Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell
Journal:  Ann Am Thorac Soc       Date:  2014-01

Review 6.  Newborn screening for cystic fibrosis: a lesson in public health disparities.

Authors:  Lainie Friedman Ross
Journal:  J Pediatr       Date:  2008-09       Impact factor: 4.406

7.  Cystic fibrosis mortality trends in Spain among infants and young children: 1981-2004.

Authors:  Enrique Ramalle-Gomara; Milagros Perucha; María-Angeles González; Carmen Quiñones; Jesús Andrés; Manuel Posada
Journal:  Eur J Epidemiol       Date:  2008-06-13       Impact factor: 8.082

8.  Differences in immunoreactive trypsin values between type of feeding and ethnicity in neonatal cystic fibrosis screening: a cross-sectional study.

Authors:  Ernesto Cortés; Ana María Roldán; Antonio Palazón-Bru; María Mercedes Rizo-Baeza; Herminia Manero; Vicente Francisco Gil-Guillén
Journal:  Orphanet J Rare Dis       Date:  2014-11-07       Impact factor: 4.123

9.  Association Between Outcomes and Demographic Factors in an Azeri Turkish Population With Cystic Fibrosis: A Cross-Sectional Study in Iran From 2001 Through 2014.

Authors:  Leila Vahedi; Morteza Jabarpoor-Bonyadi; Morteza Ghojazadeh; Hakimeh Hazrati; Mandana Rafeey
Journal:  Iran Red Crescent Med J       Date:  2016-01-06       Impact factor: 0.611

Review 10.  Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Authors:  Kamini Jain; Claire Wainwright; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.